Regulatory signals, trial wins and setbacks shape biotech outlook. December 17, 2025 1. FDA weighs black box warning for COVID-19 vaccines: 7 notes Full story 2. Sanofi MS drug faces FDA delay, trial failure Full story 3. Price isn't everything…
Life Sciences
Updates on GLP-1 deals, recalls and federal probes. December 10, 2025 1. Pfizer inks $2B deal for early-stage GLP-1 Full story 2. FDA expands COVID vaccine death review to include adults Full story 3. New data: How value analysis and…
Regulators consider changes to GLP-1 use and vaccine approvals. December 3, 2025 1. WHO issues 1st guideline on GLP-1s: 4 updates Full story 2. FDA floats changes to vaccine approval process: 5 notes Full story 3. Margins, power brokers &…
Vaccine durability questions, gene therapy gains and FDA policy concerns. November 26, 2025 1. Novo Nordisk GLP-1 fails to slow Alzheimer's in trials Full story 2. Measles vaccine immunity fades after 10 years: Study Full story 3. 2026 strategy check:…
From gene therapy cuts to HIV tests, the key FDA moves this week. November 19, 2025 1. After patient deaths, FDA to trim gene therapy's approval Full story 2. Pfizer to sell $508M stake in BioNTech Full story 3. Prevention…
Drug recalls, FDA updates and a $10B Pfizer deal lead this week. November 12, 2025 1. Pfizer prevails in $10B bidding war for Metsera Full story 2. Texas files 2nd lawsuit against Tylenol makers Full story 3. 2026 AI priorities:…
Mergers, recalls and drug shortages shaping pharma this week. November 5, 2025 1. Pfizer sues Metsera, Novo Nordisk over failed merger Full story 2. Kimberly-Clark to buy Tylenol maker Kenvue for $48.7B Full story 3. In a burnout era, 95%+…
Regulatory action, trial pauses and renewed cancer drug approvals October 29, 2025 1. Texas sues Tylenol makers, alleging drug's links to autism Full story 2. FDA approves cancer drug previously pulled from market Full story 3. Stop chasing short-term fixes.…
Pharma regulation, approvals and policy developments to watch October 22, 2025 1. Tylenol maker defends product amid FDA scrutiny Full story 2. FDA taps 1st 9 drugs for fast-track program Full story 3. Missed codes = missed revenue. How top…
FDA approvals, GLP-1 updates and new cancer research tools. October 15, 2025 1. FDA approves drug for high-risk skin cancer Full story 2. 5 GLP-1 updates Full story 3. Why ASC leaders are rethinking robotics: Lessons from UCSD and Memorial…